Tobramycin is an antibiotic used to treat bacterial infections in three main ways: as an inhaled mist for chronic lung infections (especially in cystic fibrosis), as eye drops for surface-level eye infections, and as an injection for serious body-wide infections like sepsis and meningitis. It belongs to a class of antibiotics called aminoglycosides, which work by stopping bacteria from building the proteins they need to survive. Tobramycin is particularly effective against gram-negative bacteria, the type responsible for many hospital-acquired and hard-to-treat infections.
Lung Infections in Cystic Fibrosis
The most widely recognized use of tobramycin is as an inhaled treatment for people with cystic fibrosis who have a chronic lung infection caused by Pseudomonas aeruginosa. This bacterium thrives in the thick, sticky mucus that builds up in the lungs of cystic fibrosis patients, and once it takes hold, it’s nearly impossible to fully eradicate. Inhaled tobramycin helps keep the infection controlled and slows lung damage over time.
The standard inhaled dose is 300 mg, delivered through a nebulizer twice a day. Treatment follows a distinctive on/off pattern: 28 days of using the medication, followed by 28 days off, then repeating the cycle. This schedule helps reduce the risk of bacteria becoming resistant to the drug while still keeping bacterial levels in check. The FDA has approved inhaled tobramycin for adults and children aged 6 and older.
Using the nebulizer takes some preparation. You squeeze the contents of a single-use ampule into a nebulizer cup, connect it to a compressor, and breathe the mist through a mouthpiece while sitting or standing upright. Each session typically takes about 15 minutes. The medication should look clear with no particles floating in it. If it appears cloudy, it shouldn’t be used.
Eye Infections
Tobramycin is available as a 0.3% eye drop solution (sold under the brand name Tobrex, among others) for bacterial infections on the surface of the eye and surrounding structures. It’s effective against a broad range of bacteria that commonly cause eye infections, including staph, strep, and Pseudomonas species, as well as several others like Haemophilus influenzae and Moraxella. It even works against some penicillin-resistant staph strains.
Eye drops are used for conditions like bacterial conjunctivitis (pink eye), corneal ulcers, and infections of the eyelids. Because the medication stays on the surface of the eye rather than entering the bloodstream in significant amounts, the serious side effects associated with injectable tobramycin are not a major concern with the ophthalmic form.
Serious Systemic Infections
When given by injection, tobramycin treats life-threatening infections throughout the body. The FDA lists its approved uses as including sepsis (a dangerous bloodstream infection) in both adults and children, caused by bacteria like Pseudomonas aeruginosa, E. coli, and Klebsiella species. It’s also indicated for serious central nervous system infections such as meningitis.
Injectable tobramycin is typically reserved for severe infections because it carries real risks to the ears and kidneys. It’s often used in combination with other antibiotics rather than alone. Recent guidance from the Infectious Diseases Society of America also supports once-daily tobramycin as a treatment option for complicated urinary tract infections caused by highly drug-resistant Pseudomonas, since the drug concentrates in the kidneys and maintains activity there for an extended period.
Side Effects Worth Knowing About
The two most important risks with injectable tobramycin are damage to the ears and damage to the kidneys. These risks are dose-related, meaning they increase with higher doses and longer treatment courses.
Ear damage, called ototoxicity, can affect both hearing and balance. Early symptoms include ringing in the ears (tinnitus), dizziness, and vertigo. Hearing loss tends to start with high-pitched sounds and can be permanent. Kidney damage shows up as changes in how well the kidneys filter waste, sometimes causing reduced urine output. Both risks are the reason blood levels of the drug are carefully monitored during treatment.
Certain medications make these risks worse. Loop diuretics, a common type of water pill used for swelling and heart failure, can raise tobramycin levels in the blood when given together. This combination increases the chances of both hearing and kidney damage, so healthcare teams watch patients closely when both drugs are needed at the same time.
Blood Level Monitoring
Because the gap between an effective dose and a harmful dose is narrow, hospitals routinely check tobramycin levels in the blood during injectable treatment. The goal is to get levels high enough to kill bacteria during peak concentration, then let them drop low enough between doses to give the kidneys and ears a break. Trough levels (the lowest point before the next dose) are generally kept below 1 to 2 micrograms per milliliter. Peak targets vary depending on how severe the infection is, ranging from 4 to 6 for urinary tract infections up to 20 to 30 for cystic fibrosis patients receiving IV treatment.
This monitoring is one reason injectable tobramycin is used almost exclusively in hospitals or closely supervised outpatient settings. The inhaled and eye drop forms don’t require this kind of monitoring because so little of the drug reaches the bloodstream.
How Bacteria Become Resistant
Bacteria can develop resistance to tobramycin primarily by producing enzymes that chemically alter the drug’s structure. These enzymes attach small chemical groups to the antibiotic molecule, changing its shape just enough that it can no longer bind to its target inside the bacterial cell. Three different families of these enzymes exist, each modifying the drug in a slightly different way. This is one reason the 28-day on/off cycle matters for inhaled tobramycin: giving bacteria less continuous exposure to the drug helps slow the development of resistance.